Kepley Christopher L
Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Virginia Commonwealth University Health Systems, Richmond, VA 23298, USA.
Int Arch Allergy Immunol. 2005 Sep;138(1):29-39. doi: 10.1159/000087355. Epub 2005 Aug 8.
The high-affinity IgE receptor, FcepsilonRI, is unresponsive on mast cells and basophils from people in several populations through an unknown mechanism. Similarly, FcepsilonRI-positive basophils from 'nonreleasers' are IgE-unresponsive and are deficient in the tyrosine kinase Syk.
To test the hypothesis that cross-linking FcepsilonRI on mast cells and basophils leads to FcepsilonRI nonresponsiveness through reduction in Syk protein levels.
Human mast cells and basophils were used to determine if FcepsilonRI hyporesponsiveness correlated with reduced Syk levels.
It is shown that suboptimal antigen challenge, that did not lead to significant mediator release, induced nonresponsiveness and correlated with reduced Syk. Other IgE-associated signaling molecules were unaffected by the same treatment. The ability of IgE-unresponsive mast cells to regain FcepsilonRI responsiveness is paralleled by increased cellular Syk levels in vitro. The reduction of Syk levels with suboptimal antigen concentrations was calcium independent and mediated through a proteasome-dependent mechanism.
These findings confirm and extend our knowledge about a novel regulatory mechanism for maintaining FcepsilonRI in a quiescent state. This mechanism may also explain why low concentrations of allergen given to patients during allergen immunotherapy induce FcepsilonRI nonresponsiveness and therapeutic benefit without inducing systemic anaphylaxis.
高亲和力IgE受体FcepsilonRI在来自多个人群的肥大细胞和嗜碱性粒细胞上通过未知机制无反应。同样,来自“非释放者”的FcepsilonRI阳性嗜碱性粒细胞对IgE无反应,且缺乏酪氨酸激酶Syk。
检验肥大细胞和嗜碱性粒细胞上FcepsilonRI交联通过降低Syk蛋白水平导致FcepsilonRI无反应性这一假说。
用人肥大细胞和嗜碱性粒细胞确定FcepsilonRI低反应性是否与Syk水平降低相关。
结果显示,未导致显著介质释放的次优抗原刺激诱导了无反应性,并与Syk减少相关。相同处理未影响其他IgE相关信号分子。体外IgE无反应性肥大细胞恢复FcepsilonRI反应性的能力与细胞Syk水平升高平行。次优抗原浓度导致的Syk水平降低不依赖钙,且通过蛋白酶体依赖机制介导。
这些发现证实并扩展了我们对维持FcepsilonRI处于静止状态的新型调节机制的认识。该机制也可能解释为什么在变应原免疫治疗期间给予患者低浓度变应原会诱导FcepsilonRI无反应性和治疗益处,而不诱导全身性过敏反应。